AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 4 - (NewsRx.com & NewsRx.net) -- A highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope conferred protection against experimental meningococcal bacteremia.
According to a study from England, "Inner-core lipopolysaccharide (LPS) from Neisseria meningitidis is under investigation as a vaccine for prevention of meningococcal disease caused by N. meningitidis serogroup B (NmB). We investigated the functional activity of murine monoclonal antibody (MAb) B5 that recognizes a highly conserved (galE) LPS epitope."
"Three patterns of MAb reactivity were observed in N. meningitidis by Western blot, depending on the relative prevalence of sialylated, nonsialylated, and/or truncated LPS glycoforms," reported Joyce S. Plested and colleagues at the University of Oxford and Churchill Hospital. "Three representative N. meningitidis strains (8047, M986, and 2996) were investigated with MAb B5 in functional assays in vitro and in vivo. MAb B5 completely protected infant rats against bacteremia caused by 8047, partially protected against 2996, and had no protective activity against M986."
The investigators concluded, "Thus, ...
Source: HighBeam Research, Lipopolysaccharide epitope protects against meningococcal bacteremia.